| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Friederike Held, Sudhakar Reddy Kalluri, Achim Berthele, Ana-Katharina Klein, Markus Reindl, Bernhard Hemme. Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients. Multiple sclerosis journal - experimental, translational and clinical. vol 7. issue 2. 2021-07-16. PMID:34262784. |
myelin oligodendrocyte glycoprotein (mog) antibody disease (mog-ad) is recognized as a distinct nosological entity. |
2021-07-16 |
2023-08-13 |
Not clear |
| Andres Server Alonso, Tomas Sakinis, Helle Cecilie V Pfeiffer, Inger Sandvig, Jon Barlinn, Pål B Marthinse. Understanding Pediatric Neuroimmune Disorder Conflicts: A Neuroradiologic Approach in the Molecular Era. Radiographics : a review publication of the Radiological Society of North America, Inc. vol 40. issue 5. 2021-07-14. PMID:32735475. |
the authors focus on pediatric-onset myelin oligodendrocyte glycoprotein (mog) antibody-associated disease, which is a new entity in the spectrum of inflammatory demyelinating diseases, distinct from both multiple sclerosis (ms) and anti-aquaporin-4 (aqp4) antibody neuromyelitis optica spectrum disorders (nmosds). |
2021-07-14 |
2023-08-13 |
Not clear |
| Laetitia Pouzol, Nadège Baumlin, Anna Sassi, Mélanie Tunis, Julia Marrie, Enrico Vezzali, Hervé Farine, Ulrich Mentzel, Marianne M Martini. ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. vol 35. issue 3. 2021-07-13. PMID:33595155. |
the effect of act-1004-1239 was evaluated in the myelin oligodendrocyte glycoprotein (mog)-induced experimental autoimmune encephalomyelitis (eae) and the cuprizone-induced demyelination mouse models. |
2021-07-13 |
2023-08-13 |
mouse |
| Shunsuke Yoshimura, Shinsuke Nakagawa, Toshiyuki Takahashi, Keiko Tanaka, Akira Tsujin. FTY720 Exacerbates Blood-Brain Barrier Dysfunction Induced by IgG Derived from Patients with NMO and MOG Disease. Neurotoxicity research. vol 39. issue 4. 2021-07-13. PMID:33999356. |
neuromyelitis optica (nmo) and myelin oligodendrocyte glycoprotein (mog) antibody-related disease (mog disease) are inflammatory demyelinating diseases of the central nervous system (cns). |
2021-07-13 |
2023-08-13 |
rat |
| Matthew C Mason, Dario A Marotta, Hassan Kesserwan. Isolated Double-Positive Optic Neuritis: A Case of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibody Seropositivity. Cureus. vol 13. issue 6. 2021-07-13. PMID:34249541. |
these conditions are usually accompanied by multi-level spinal cord demyelination, and notably, they are typically positive for either nmo or myelin oligodendrocyte glycoprotein (mog) autoantibodies, but rarely both. |
2021-07-13 |
2023-08-13 |
Not clear |
| Joseph H Choe, Payal B Watchmaker, Milos S Simic, Ryan D Gilbert, Aileen W Li, Nira A Krasnow, Kira M Downey, Wei Yu, Diego A Carrera, Anna Celli, Juhyun Cho, Jessica D Briones, Jason M Duecker, Yitzhar E Goretsky, Ruth Dannenfelser, Lia Cardarelli, Olga Troyanskaya, Sachdev S Sidhu, Kole T Roybal, Hideho Okada, Wendell A Li. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Science translational medicine. vol 13. issue 591. 2021-07-12. PMID:33910979. |
a synnotch receptor that recognizes a specific priming antigen, such as the heterogeneous but tumor-specific glioblastoma neoantigen epidermal growth factor receptor splice variant iii (egfrviii) or the central nervous system (cns) tissue-specific antigen myelin oligodendrocyte glycoprotein (mog), can be used to locally induce expression of a car. |
2021-07-12 |
2023-08-13 |
mouse |
| C L de Mol, Yym Wong, E D van Pelt, Bha Wokke, Tam Siepman, R F Neuteboom, D Hamann, R Q Hintze. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Multiple sclerosis (Houndmills, Basingstoke, England). vol 26. issue 7. 2021-07-09. PMID:31094288. |
the aim of this study was to assess the dutch nationwide incidence of myelin oligodendrocyte glycoprotein (mog)-igg-associated acquired demyelinating syndromes (ads) and to describe the clinical and serological characteristics of these patients. |
2021-07-09 |
2023-08-13 |
Not clear |
| Fiona Costello, John J Che. The role of optical coherence tomography in the diagnosis of afferent visual pathway problems: A neuroophthalmic perspective. Handbook of clinical neurology. vol 178. 2021-07-09. PMID:33832689. |
on a more pragmatic level, oct is used in the clinical arena to diagnose on associated with: ms, neuromyelitis optica spectrum disorder (nmosd), and myelin oligodendrocyte glycoprotein (mog) antibody associated disease (mogad). |
2021-07-09 |
2023-08-13 |
Not clear |
| Mena Farag, Naomi Sibtain, James Burge, Vinay Chaudhry, Eli Silbe. Atypical inflammatory demyelinating syndrome with central and peripheral nerve involvement. Multiple sclerosis and related disorders. vol 51. 2021-07-07. PMID:34049139. |
oligoclonal bands (ocbs) were matched and serum antibodies against aquaporin-4 (aqp-4) and myelin oligodendrocyte glycoprotein (mog) were negative. |
2021-07-07 |
2023-08-13 |
Not clear |
| Amy Li Safadi, Cory J Myers, Nancy N Hu, Benjamin Osborn. Conus involvement and leptomeningeal enhancement in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: A case report. Multiple sclerosis and related disorders. vol 52. 2021-07-06. PMID:34015641. |
we discuss the factors that complicated a timely diagnosis, including her atypical radiographic features and an initially negative cell-based assay for myelin oligodendrocyte glycoprotein (mog) and aquaporin-4 (aqp4) antibodies. |
2021-07-06 |
2023-08-13 |
Not clear |
| Min Sung Kang, Min Kyoung Kim, Ye Eun Kim, Ji Hyun Kim, Byoung Joon Kim, Hye Lim Le. Two cases of myelin oligodendrocyte glycoprotein antibody-associated disease presenting with Cauda Equina Syndrome without conus myelitis. Multiple sclerosis and related disorders. vol 52. 2021-07-06. PMID:34023773. |
myelin oligodendrocyte glycoprotein antibody-associated disorder (mogad) is a central nervous system inflammatory disorder associated with mog antibodies. |
2021-07-06 |
2023-08-13 |
Not clear |
| Weibi Chen, Qian Li, Ting Wang, Linlin Fan, Lehong Gao, Zhaoyang Huang, Yicong Lin, Qin Xue, Gang Liu, Yingying Su, Yan Zhan. Overlapping syndrome of anti-N-methyl-D-aspartate receptor encephalitis and anti-myelin oligodendrocyte glycoprotein inflammatory demyelinating diseases: A distinct clinical entity? Multiple sclerosis and related disorders. vol 52. 2021-07-06. PMID:34034214. |
the co-existence of anti-n-methyl-d-aspartate receptor encephalitis (nmdare) and anti-myelin oligodendrocyte glycoprotein (mog) antibody disease has sparsely been reported, which needs to be investigated. |
2021-07-06 |
2023-08-13 |
Not clear |
| Manish Malviya, Abdelhadi Saoudi, Jan Bauer, Simon Fillatreau, Roland Libla. Treatment of experimental autoimmune encephalomyelitis with engineered bi-specific Foxp3+ regulatory CD4+ T cells. Journal of autoimmunity. vol 108. 2021-07-05. PMID:31948790. |
in this study, we examined whether tregs engineered through retroviral transduction to express a tcr cross-reactive to two cns autoantigens, myelin oligodendrocyte glycoprotein (mog) and neurofilament-medium (nf-m), had a superior protective efficacy compared with tregs expressing a mog mono-specific tcr. |
2021-07-05 |
2023-08-13 |
Not clear |
| Sidney M Gospe, John J Chen, M Tariq Bhatt. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment. Eye (London, England). vol 35. issue 3. 2021-07-05. PMID:33323985. |
however, the discovery of aquaporin-4 immunoglobulin g (igg) and myelin oligodendrocyte glycoprotein (mog)-igg as biomarkers for two separate central nervous system inflammatory demyelinating diseases has revealed that neuromyelitis optica spectrum disorder (nmsod) and mog-igg-associated disease (mogad) are responsible for clinically distinct subsets of on. |
2021-07-05 |
2023-08-13 |
Not clear |
| Jacqueline F Rosenthal, Benjamin M Hoffman, William R Tyo. CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. vol 68. issue 2. 2021-07-02. PMID:31582425. |
neuromyelitis optica spectrum disorder (nmosd) and myelin oligodendrocyte glycoprotein (mog) antibody-associated disease are less common but share some clinical characteristics, such as optic neuritis and myelitis, which can make a specific diagnosis challenging. |
2021-07-02 |
2023-08-13 |
Not clear |
| Fatemeh Mohammadi-Milasi, Karim Mahnam, Mostafa Shakhsi-Niae. In silico study of the association of the HLA-A*31:01 allele (human leucocyte antigen allele 31:01) with neuroantigenic epitopes of PLP (proteolipid protein), MBP (myelin basic protein) and MOG proteins (myelin oligodendrocyte glycoprotein) for studying the multiple sclerosis disease pathogenesis. Journal of biomolecular structure & dynamics. vol 39. issue 7. 2021-07-02. PMID:32242486. |
in silico study of the association of the hla-a*31:01 allele (human leucocyte antigen allele 31:01) with neuroantigenic epitopes of plp (proteolipid protein), mbp (myelin basic protein) and mog proteins (myelin oligodendrocyte glycoprotein) for studying the multiple sclerosis disease pathogenesis. |
2021-07-02 |
2023-08-13 |
human |
| Fatemeh Mohammadi-Milasi, Karim Mahnam, Mostafa Shakhsi-Niae. In silico study of the association of the HLA-A*31:01 allele (human leucocyte antigen allele 31:01) with neuroantigenic epitopes of PLP (proteolipid protein), MBP (myelin basic protein) and MOG proteins (myelin oligodendrocyte glycoprotein) for studying the multiple sclerosis disease pathogenesis. Journal of biomolecular structure & dynamics. vol 39. issue 7. 2021-07-02. PMID:32242486. |
plp (proteolipid protein), mpb (myelin basic protein), and myelin oligodendrocyte glycoprotein (mog) proteins are important autoantigens for the demyelinating of cns in multiple sclerosis. |
2021-07-02 |
2023-08-13 |
human |
| Yue Jia, Dandan Zhang, Haoran Li, Shaolei Luo, Yuhuan Xiao, Li Han, Fuchun Zhou, Chuanyue Wang, Lei Feng, Gang Wang, Peng Wu, Chunjie Xiao, Haijing Yu, Jing Du, Hongkun Ba. Activation of FXR by ganoderic acid A promotes remyelination in multiple sclerosis via anti-inflammation and regeneration mechanism. Biochemical pharmacology. vol 185. 2021-07-01. PMID:33482151. |
here, we reported that ganoderic acid a (gaa) significantly enhanced the remyelination and rescued motor deficiency in two animal models of ms, including cuprizone-induced demyelination and myelin oligodendrocyte glycoprotein (mog) 35-55-induced experimental autoimmune encephalomyelitis model. |
2021-07-01 |
2023-08-13 |
mouse |
| Rina Aharoni, Renana Globerman, Raya Eilam, Ori Brenner, Ruth Arno. Titration of myelin oligodendrocyte glycoprotein (MOG) - Induced experimental autoimmune encephalomyelitis (EAE) model. Journal of neuroscience methods. vol 351. 2021-06-30. PMID:33189793. |
titration of myelin oligodendrocyte glycoprotein (mog) - induced experimental autoimmune encephalomyelitis (eae) model. |
2021-06-30 |
2023-08-13 |
mouse |
| Rina Aharoni, Renana Globerman, Raya Eilam, Ori Brenner, Ruth Arno. Titration of myelin oligodendrocyte glycoprotein (MOG) - Induced experimental autoimmune encephalomyelitis (EAE) model. Journal of neuroscience methods. vol 351. 2021-06-30. PMID:33189793. |
experimental autoimmune encephalomyelitis (eae) induced by the myelin oligodendrocyte glycoprotein (mog) peptide 35-55, is a widely used multiple sclerosis (ms) model. |
2021-06-30 |
2023-08-13 |
mouse |